- Previous Close
2.7400 - Open
2.7000 - Bid 1.9200 x 100
- Ask 3.2800 x 200
- Day's Range
2.5400 - 2.7300 - 52 Week Range
2.1700 - 8.4500 - Volume
82,035 - Avg. Volume
262,400 - Market Cap (intraday)
130.898M - Beta (5Y Monthly) 2.51
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0300 - Earnings Date Apr 30, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.50
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform procedures for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure; and SION surgical instrument, a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also offers TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
www.sightsciences.comRecent News: SGHT
View MorePerformance Overview: SGHT
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SGHT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SGHT
View MoreValuation Measures
Market Cap
130.90M
Enterprise Value
50.90M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.60
Price/Book (mrq)
1.50
Enterprise Value/Revenue
0.64
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-64.49%
Return on Assets (ttm)
-20.41%
Return on Equity (ttm)
-49.59%
Revenue (ttm)
79.87M
Net Income Avi to Common (ttm)
-51.51M
Diluted EPS (ttm)
-1.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
120.36M
Total Debt/Equity (mrq)
46.12%
Levered Free Cash Flow (ttm)
-5.54M